Raphael Pharmaceutical (RAPH) Cash & Current Investments (2020 - 2026)
Raphael Pharmaceutical's (RAPH) quarterly Cash & Current Investments came in at $1000.0 in Q2 2026, down 95.0% year-over-year from $20000.0 in Q2 2025, and down 97.78% quarter-over-quarter from $45000.0 in Q4 2025.
Powered by 
Analysis
Raphael Pharmaceutical (RAPH) Cash & Current Investments (2020 - 2026) Analysis & Trends
Raphael Pharmaceutical has disclosed Cash & Current Investments across 7 years of filings, most recently posting $1000.0 for Q2 2026.
- In Q2 2026, Cash & Current Investments fell 95.0% year-over-year to $1000.0; the TTM figure through Jun 2026 stood at $1000.0 (down 95.0% YoY), while the FY2025 annual figure was $45000.0, up 136.84% from the prior year.
- Cash & Current Investments came in at $1000.0 for Q2 2026 at Raphael Pharmaceutical, down from $45000.0 in the prior quarter.
- In the past five years, Cash & Current Investments ranged from a high of $299000.0 in Q3 2023 to a low of $1000.0 in Q2 2026.
- Average Cash & Current Investments over 5 years is $109411.8, with a median of $81000.0 recorded in 2022.
- Year-over-year, Cash & Current Investments surged 655.26% in 2024 and plunged 95.0% in 2026.
- Over 5 years, Cash & Current Investments stood at $288000.0 in 2022, then retreated by 20.14% to $230000.0 in 2023, then plunged by 91.74% to $19000.0 in 2024, then soared by 136.84% to $45000.0 in 2025, then tumbled by 97.78% to $1000.0 in 2026.
- Per Business Quant data, the three most recent Cash & Current Investments figures were $1000.0 in Q2 2026, $45000.0 in Q4 2025, and $3000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 13.99 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 3.18 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 7.85 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 7.99 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 5.18 Bn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 5.14 Bn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 3.31 Bn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 1.29 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | - |
| 10 | Raphael Pharmaceutical | 28.25 Mn | 28.25 Mn | - | 1,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1,000.00 |
| Dec 31, 2025 | 45,000.00 |
| Sep 30, 2025 | 3,000.00 |
| Jun 30, 2025 | 20,000.00 |
| Mar 31, 2025 | 50,000.00 |
| Dec 31, 2024 | 19,000.00 |
| Sep 30, 2024 | 40,000.00 |
| Jun 30, 2024 | 120,000.00 |
| Mar 31, 2024 | 287,000.00 |
| Dec 31, 2023 | 230,000.00 |
| Sep 30, 2023 | 299,000.00 |
| Jun 30, 2023 | 111,000.00 |
| Mar 31, 2023 | 38,000.00 |
| Dec 31, 2022 | 288,000.00 |
| Sep 30, 2022 | 93,000.00 |
| Jun 30, 2022 | 135,000.00 |
| Mar 31, 2022 | 81,000.00 |
| Dec 31, 2021 | 153,000.00 |
| Sep 30, 2021 | 37,000.00 |
| Dec 31, 2020 | 95,000.00 |